Nuvectis Pharma Inc (NVCT)
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications with unmet medical need. The company is advancing NXP900, a small-molecule candidate being evaluated in a Phase 1b clinical trial for solid tumors. NXP900 is designed to inhibit the c-Src and YES1 kinases. Founded in 2020 and based in Fort Lee, New Jersey, the company adopted the Nuvectis Pharma name in July 2021 after previously operating as Centry Pharma, Inc. The listed security is common stock on NASDAQ under the symbol NVCT.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NVCT
|
$11.57
|
-47.4% Downside
|
Overvalued
|
$35.40
|
60.9% Upside
|
Bargain
|
Fair
|
0.0%
|
November 10, 2026
|
78.9x
|
716.8 M
|
694.6 M
|
0.0%
|
65.1%
|
21.5
|
64.4%
|
